Novel Immunotherapies for T Cell Lymphoma and Leukemia.
Novel Immunotherapies for T Cell Lymphoma and Leukemia.
复制标题
DOI：
10.1007/s11899-018-0480-8
复制
发表时间：
2018-12
影响因子：
2.9
通讯作者：
Ruella M
中科院分区：
文献类型：
--
作者：
Ghione P;Moskowitz AJ;De Paola NEK;Horwitz SM;Ruella M
新的免疫疗法，如检查点抑制剂、双特异性和嵌合抗原受体T细胞，在治疗实体瘤和血液系统恶性肿瘤时产生了有希望的反应。T细胞肿瘤包括来源于T细胞的白血病和淋巴瘤。这些都是罕见疾病，临床结果通常很差。本文综述了这些方法治疗T细胞淋巴瘤和白血病的合理性和初步结果。对于T细胞肿瘤，尽管进行了大量的研究，但只有少数药物，如单克隆抗体和同种异体干细胞移植，显示出一些临床活性。靶向T细胞肿瘤的主要障碍之一是激活或消除T细胞，无论是正常的还是肿瘤的，都会引起显著的毒性。需要开发新的安全有效的T细胞肿瘤免疫疗法。在这篇综述中，我们将讨论免疫治疗T细胞白血病和淋巴瘤的基本原理，并介绍最新的治疗方法。
novel immunotherapies such as checkpoint inhibitors, bispecific and chimeric antigen receptor T cells are leading to promising responses when treating solid tumors and hematological malignancies. T cell neoplasms include leukemia and lymphomas that are derived from T cells. These are rare diseases with generally poor clinical outcomes. This review describes the rational and preliminary results of these approaches for people with T cell lymphoma and leukemia. for T cell neoplasms, despite significant research effort, only few agents, such as monoclonal antibodies and allogeneic stem cell transplantation, showed some clinical activity. One of the major hurdles to targeting T cell neoplasms is that activation or elimination of T cells, either normal or neoplastic, can cause significant toxicity. A need to develop novel safe and effective immunotherapies for T cell neoplasms exists. In this review, we will discuss the rationale for immunotherapy of T cell leukemia and lymphoma and present the most recent therapeutic approaches.
登录
查看更多内容
影响因子：
3.7
作者：
Barros MH;Segges P;Vera-Lozada G;Hassan R;Niedobitek G
通讯作者：
Niedobitek G
影响因子：
10.1
作者：
Bellei M;Foss FM;Shustov AR;Horwitz SM;Marcheselli L;Kim WS;Cabrera ME;Dlouhy I;Nagler A;Advani RH;Pesce EA;Ko YH;Martinez V;Montoto S;Chiattone C;Moskowitz A;Spina M;Biasoli I;Manni M;Federico M;International T-cell Project Network
通讯作者：
International T-cell Project Network
影响因子：
11.5
作者：
Barros, Mario Henrique M.;Hassan, Rocio;Niedobitek, Gerald
通讯作者：
Niedobitek, Gerald
DOI：
10.1056/nejmoa1200694
发表时间：
2012-06-28
期刊：
The New England journal of medicine
影响因子：
--
作者：
Brahmer JR;Tykodi SS;Chow LQ;Hwu WJ;Topalian SL;Hwu P;Drake CG;Camacho LH;Kauh J;Odunsi K;Pitot HC;Hamid O;Bhatia S;Martins R;Eaton K;Chen S;Salay TM;Alaparthy S;Grosso JF;Korman AJ;Parker SM;Agrawal S;Goldberg SM;Pardoll DM;Gupta A;Wigginton JM
通讯作者：
Wigginton JM
影响因子：
39.2
作者：
BUNN, PA;FOON, KA;OLDHAM, R
通讯作者：
OLDHAM, R